JP7118449B2 - 胃腸ポリープの処置のための組成物及び方法 - Google Patents
胃腸ポリープの処置のための組成物及び方法 Download PDFInfo
- Publication number
- JP7118449B2 JP7118449B2 JP2019547199A JP2019547199A JP7118449B2 JP 7118449 B2 JP7118449 B2 JP 7118449B2 JP 2019547199 A JP2019547199 A JP 2019547199A JP 2019547199 A JP2019547199 A JP 2019547199A JP 7118449 B2 JP7118449 B2 JP 7118449B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compositions
- administration
- independently
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/32—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and esterified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
- C07C229/58—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/62—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino groups and at least two carboxyl groups bound to carbon atoms of the same six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
R1、R3、R5は、それぞれ独立して、OD、OCH3、OCOCH3、無し、
R2、R4、R6は、それぞれ独立して、
nは、独立して、1、2、3、4又は5であり;
aは、独立して、2、3又は7であり;
それぞれのbは、独立して、3、5又は6であり;
eは、独立して、1、2又は6であり;
c及びdは、それぞれ独立して、H、D、-OH、-OD、C1~C6アルキル、-NH2又は-COCH3である]
の化合物及び組成物、又は薬学的に許容されるその塩並びに薬学的に許容されるその塩、水和物、溶媒和物、プロドラッグ、エナンチオマー及び立体異性体に関する。
nは、独立して、1、2、3、4又は5であり;
aは、独立して、2、3又は7であり;
それぞれのbは、独立して、3、5又は6であり;
eは、独立して、1、2又は6であり;
c及びdは、それぞれ独立して、H、D、-OH、-OD、C1~C6アルキル、-NH2又は-COCH3である]
の化合物並びに薬学的に許容されるその塩、水和物、溶媒和物、プロドラッグ、エナンチオマー及び立体異性体が記載される。
nは、独立して、1、2、3、4又は5であり;
aは、独立して、2、3又は7であり;
それぞれのbは、独立して、3、5又は6であり;
eは、独立して、1、2又は6であり;
c及びdは、それぞれ独立して、H、D、-OH、-OD、C1~C6アルキル、-NH2又は-COCH3である]
の化合物並びに薬学的に許容されるその塩、水和物、溶媒和物、プロドラッグ、エナンチオマー及び立体異性体が記載される。
nは、独立して、1、2、3、4又は5であり;
aは、独立して、2、3又は7であり;
それぞれのbは、独立して、3、5又は6であり;
eは、独立して、1、2又は6であり;
c及びdは、それぞれ独立して、H、D、-OH、-OD、C1~C6アルキル、-NH2又は-COCH3である]
の化合物並びに薬学的に許容されるその塩、水和物、溶媒和物、プロドラッグ、エナンチオマー及び立体異性体が記載される。
nは、独立して、1、2、3、4又は5であり;
aは、独立して、2、3又は7であり;
それぞれのbは、独立して、3、5又は6であり;
eは、独立して、1、2又は6であり;
c及びdは、それぞれ独立して、H、D、-OH、-OD、C1~C6アルキル、-NH2又は-COCH3である]
の化合物並びに薬学的に許容されるその塩、水和物、溶媒和物、プロドラッグ、エナンチオマー及び立体異性体が記載される。
nは、独立して、1、2、3、4又は5であり;
aは、独立して、2、3又は7であり;
それぞれのbは、独立して、3、5又は6であり;
eは、独立して、1、2又は6であり;
c及びdは、それぞれ独立して、H、D、-OH、-OD、C1~C6アルキル、-NH2又は-COCH3である]
の化合物並びに薬学的に許容されるその塩、水和物、溶媒和物、プロドラッグ、エナンチオマー及び立体異性体が記載される。
本明細書で使用される場合、以下の用語及び語句は、下記に説明する意味を有するものとする。他に定義されない限り、本明細書で使用されるすべての技術用語及び科学用語は、当業者に一般に理解されているものと同じ意味を有する。
nは、独立して、1、2、3、4又は5であり;
aは、独立して、2、3又は7であり;
それぞれのbは、独立して、3、5又は6であり;
eは、独立して、1、2又は6であり;
c及びdは、それぞれ独立して、H、D、-OH、-OD、C1~C6アルキル、-NH2又は-COCH3である]
の化合物並びに薬学的に許容されるその塩、水和物、溶媒和物、プロドラッグ、エナンチオマー及び立体異性体を、それを必要とする患者に投与することを含む、方法を提供する。
式Iの化合物を製造するために有用な合成経路の例を、下記の例で説明し、スキーム1、スキーム2、スキーム3、スキーム4及びスキーム5において、一般化する。
本開示は、とりわけ、胃腸ポリープ及びこれらの合併症を処置するための組成物及び方法を提供する。主題の開示の特定の実施形態を議論してきたが、上記の明細書は例示的なものであって、限定的なものではない。本明細書におけるシステム及び方法の多くの変形は、本明細書を検討することにより、当業者に明らかになるであろう。特許請求の範囲に係るシステム及び方法の完全な範囲は、特許請求の範囲と共にそれらの均等物の完全な範囲、及び明細書と共にこのような変形例を参照することによって、決定されるべきである。
上記に列挙したものを含む、本明細書において言及されたすべての刊行物及び特許は、それぞれ個々の刊行物又は特許が参照によってあたかも具体的かつ個々に組み込まれることが示されるように、それらの全体が参照によって本明細書に組み込まれる。矛盾する場合、本明細書における任意の定義を含む、本出願が支配する。
Claims (4)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641038684 | 2016-11-11 | ||
IN201641038684 | 2016-11-11 | ||
PCT/IB2017/052241 WO2018087605A1 (en) | 2016-11-11 | 2017-04-19 | Compositions and methods for the treatment of gastrointestinal polyps |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019535824A JP2019535824A (ja) | 2019-12-12 |
JP7118449B2 true JP7118449B2 (ja) | 2022-08-16 |
Family
ID=62109214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019547199A Active JP7118449B2 (ja) | 2016-11-11 | 2017-04-19 | 胃腸ポリープの処置のための組成物及び方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11225464B2 (ja) |
EP (1) | EP3538086A4 (ja) |
JP (1) | JP7118449B2 (ja) |
KR (1) | KR102408871B1 (ja) |
CN (1) | CN110167548A (ja) |
AU (1) | AU2017357873B2 (ja) |
BR (1) | BR112019009615A2 (ja) |
CA (1) | CA3043445C (ja) |
IL (1) | IL266545B (ja) |
MX (1) | MX2019005568A (ja) |
RU (1) | RU2749188C2 (ja) |
SG (1) | SG10202104160TA (ja) |
WO (1) | WO2018087605A1 (ja) |
ZA (1) | ZA201903222B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017357873B2 (en) * | 2016-11-11 | 2022-02-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of gastrointestinal polyps |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008098375A1 (en) | 2007-02-15 | 2008-08-21 | Centre De Recherche Sur Les Biotechnologies Marines | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
WO2010095965A1 (en) | 2009-02-19 | 2010-08-26 | Farma-Projekt Sp. Z 0.0. | The use of sulindac and/or its metabolite as adjuvant treatment for colon cancer in humans |
WO2011132171A1 (en) | 2010-04-23 | 2011-10-27 | Piramal Life Sciences Limited | Nitric oxide releasing prodrugs of therapeutic agents |
WO2014068461A2 (en) | 2012-11-02 | 2014-05-08 | Mahesh Kandula | Compositions and methods for the treatment of acute inflammation |
US20140315960A1 (en) | 2011-10-31 | 2014-10-23 | Claus Selch Larsen | Prodrugs of non-steroid anti-inflammatory agents (nsaids) |
WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602910B2 (en) * | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
US20140287004A1 (en) * | 2005-11-14 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Use of an Omega-3 Lipid-Based Emulsion Following Ischemic Injury to Provide Protection and Recovery in Human Organs |
EP2650279A3 (en) * | 2008-08-19 | 2014-02-12 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US8207363B2 (en) * | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
AU2017357873B2 (en) * | 2016-11-11 | 2022-02-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of gastrointestinal polyps |
-
2017
- 2017-04-19 AU AU2017357873A patent/AU2017357873B2/en active Active
- 2017-04-19 SG SG10202104160TA patent/SG10202104160TA/en unknown
- 2017-04-19 BR BR112019009615A patent/BR112019009615A2/pt not_active IP Right Cessation
- 2017-04-19 KR KR1020197016008A patent/KR102408871B1/ko active IP Right Grant
- 2017-04-19 EP EP17869375.0A patent/EP3538086A4/en not_active Withdrawn
- 2017-04-19 CA CA3043445A patent/CA3043445C/en active Active
- 2017-04-19 JP JP2019547199A patent/JP7118449B2/ja active Active
- 2017-04-19 RU RU2019116981A patent/RU2749188C2/ru active
- 2017-04-19 WO PCT/IB2017/052241 patent/WO2018087605A1/en unknown
- 2017-04-19 US US16/348,954 patent/US11225464B2/en active Active
- 2017-04-19 MX MX2019005568A patent/MX2019005568A/es unknown
- 2017-04-19 CN CN201780083005.7A patent/CN110167548A/zh active Pending
-
2019
- 2019-05-09 IL IL266545A patent/IL266545B/en unknown
- 2019-05-22 ZA ZA2019/03222A patent/ZA201903222B/en unknown
-
2021
- 2021-12-02 US US17/457,398 patent/US20220162171A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008098375A1 (en) | 2007-02-15 | 2008-08-21 | Centre De Recherche Sur Les Biotechnologies Marines | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
WO2010095965A1 (en) | 2009-02-19 | 2010-08-26 | Farma-Projekt Sp. Z 0.0. | The use of sulindac and/or its metabolite as adjuvant treatment for colon cancer in humans |
WO2011132171A1 (en) | 2010-04-23 | 2011-10-27 | Piramal Life Sciences Limited | Nitric oxide releasing prodrugs of therapeutic agents |
US20140315960A1 (en) | 2011-10-31 | 2014-10-23 | Claus Selch Larsen | Prodrugs of non-steroid anti-inflammatory agents (nsaids) |
WO2014068461A2 (en) | 2012-11-02 | 2014-05-08 | Mahesh Kandula | Compositions and methods for the treatment of acute inflammation |
WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
Also Published As
Publication number | Publication date |
---|---|
US11225464B2 (en) | 2022-01-18 |
CA3043445A1 (en) | 2018-05-17 |
EP3538086A4 (en) | 2021-01-20 |
KR20190100178A (ko) | 2019-08-28 |
MX2019005568A (es) | 2019-09-27 |
CN110167548A (zh) | 2019-08-23 |
IL266545B (en) | 2021-10-31 |
WO2018087605A1 (en) | 2018-05-17 |
KR102408871B1 (ko) | 2022-06-15 |
CA3043445C (en) | 2023-08-22 |
BR112019009615A2 (pt) | 2019-08-13 |
RU2019116981A3 (ja) | 2020-11-30 |
EP3538086A1 (en) | 2019-09-18 |
NZ753702A (en) | 2022-03-25 |
US20200190040A1 (en) | 2020-06-18 |
AU2017357873A1 (en) | 2019-06-06 |
IL266545A (en) | 2019-07-31 |
JP2019535824A (ja) | 2019-12-12 |
US20220162171A1 (en) | 2022-05-26 |
AU2017357873B2 (en) | 2022-02-24 |
ZA201903222B (en) | 2021-08-25 |
SG10202104160TA (en) | 2021-06-29 |
RU2019116981A (ru) | 2020-11-30 |
RU2749188C2 (ru) | 2021-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102422382B1 (ko) | 통증 치료를 위한 조성물 | |
KR102442758B1 (ko) | 구강건조증(xerostomia)의 치료를 위한 조성물 및 방법 | |
KR102567089B1 (ko) | 곰팡이 감염의 치료를 위한 조성물 및 방법 | |
WO2016046680A2 (en) | Compositions and methods for the treatment of liver metabolic diseases | |
US20220162171A1 (en) | Compositions and methods for the treatment of gastrointestinal polyps | |
JP2015518854A5 (ja) | ||
US9403826B2 (en) | Compositions and methods for the treatment of inflammatory disorders | |
RU2751770C2 (ru) | Композиции и способы лечения синдрома раздраженного кишечника | |
JP2015521174A (ja) | 糖尿病の治療のための組成物および方法 | |
AU2016314617A1 (en) | Compositions and methods for the treatment of parkinson's disease | |
JP2016510306A (ja) | 高血糖の治療のための組成物及び方法 | |
WO2014147541A2 (en) | Compositions and methods for the treatment of peptic ulcers and gastrointestinal diseases | |
NZ753702B2 (en) | Compositions and methods for the treatment of gastrointestinal polyps | |
WO2015008205A2 (en) | Compositions and methods for the treatment of respiratory diseases | |
WO2015028928A2 (en) | Compositions and methods for the treatment of inflammation and arthritis | |
WO2015001499A2 (en) | Compositions and methods for the treatment of irritable bowel syndrome and the associated abdominal cramping |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210119 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20210304 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210419 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220315 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220518 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220518 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220526 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220531 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220628 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220727 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7118449 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |